# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Benchmark analyst Bill Sutherland reiterates Surgery Partners (NASDAQ:SGRY) with a Buy and maintains $50 price target.
- Bloomberg
Concentra, a subsidiary of select medical, recently priced its IPO at $23.50 per share. Concentra offers occupational health se...
Cantor Fitzgerald analyst Sarah James reiterates Surgery Partners (NASDAQ:SGRY) with a Overweight and maintains $43 price ta...
Cantor Fitzgerald analyst Sarah James reiterates Surgery Partners (NASDAQ:SGRY) with a Overweight and maintains $43 price ta...
Citigroup analyst Jason Cassorla maintains Surgery Partners (NASDAQ:SGRY) with a Buy and lowers the price target from $38 to...
Benchmark analyst Bill Sutherland reiterates Surgery Partners (NASDAQ:SGRY) with a Buy and maintains $50 price target.
RBC Capital analyst Ben Hendrix reiterates Surgery Partners (NASDAQ:SGRY) with a Outperform and maintains $49 price target.